Product Description
cytomegalovirus (CMV) peptide(Pep) vaccine(Vax) for patients with hematologic malignancies undergoing donor stem cell transplant. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02396134)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: City of Hope Medical Center
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Myelofibrosis|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Myeloid Leukemia|Myeloid, Accelerated Leukemia|Myeloproliferative Disorders|Lymphoma, Non-Hodgkin|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myelodysplastic Syndrome|Acute Lymphoid Leukemia|Lymphoma, B-Cell|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Chronic Myeloid Leukemia|Cytomegalovirus Infections|Hodgkin Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NCI-2015-00283 | P2 |
Completed |
Myelodysplastic Syndrome|Acute Myeloid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Lymphoma, B-Cell|Myelofibrosis|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Acute Lymphoid Leukemia|Hodgkin Lymphoma|Myeloproliferative Disorders|Chronic Myeloid Leukemia|Myeloid, Accelerated Leukemia|Lymphoma, Non-Hodgkin|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Cytomegalovirus Infections |
2018-03-04 |
2025-03-04 |
Primary Endpoints|Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|